20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key...
20:20 , Jun 29, 2018 |  BC Extra  |  Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
01:06 , Feb 8, 2018 |  BC Extra  |  Company News

Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business...
02:09 , Feb 3, 2018 |  BioCentury  |  Strategy

Road to acquisition

Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of...
20:31 , Feb 2, 2018 |  BC Week In Review  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.8 billion). The price is a 21% premium to Ablynx's close of...
23:11 , Jan 29, 2018 |  BC Extra  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.84 billion). The price is a 21% premium to Ablynx's close of...
00:02 , Jan 13, 2018 |  BioCentury  |  Finance

Assessing Ablynx

While a group of investors in Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) don’t agree on what is fair value for the Belgian biotech, they do think a $2.8 billion offer from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) undervalues...
18:24 , Jan 12, 2018 |  BC Week In Review  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) made public news that its board rejected two unsolicited acquisition proposals from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Ablynx said in a statement the latest proposal "fundamentally undervalues" the company. On Dec. 22,...
22:53 , Jan 8, 2018 |  BC Extra  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) gained €9.60 (45%) to €30.80 in Brussels and $12.71 (49%) to $38.62 in New York on Monday after making public news that its board rejected two unsolicited acquisition proposals from Novo...